Hydrophobically Modified let-7b miRNA Enhances Biodistribution to NSCLC and Downregulates HMGA2 In Vivo

Segal, Meirav; Biscans, Annabelle; Gilles, Maud-Emmanuelle; Anastasiadou, Eleni; Luca, Roberto De; Lim, Jihoon; Khvorova, Anastasia; Slack, Frank J.

doi:10.1016/j.omtn.2019.11.008

Cited by 44 publications

(29 citation statements)

References 66 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As it pertains to precision medicine for cancer treatment, detection of genetic aberrations is the basis of developing effective treatment options. 30 -32 Through the analysis of genetic mutations in patients with cancer, we can tailor the treatment plan for each patient with cancer to maximize the curative effect, minimize the damage, and optimize the resources. 33 -36…”

Section: Precision Medicine and Tumor Gene Detectionmentioning

confidence: 99%

“…29 As it pertains to precision medicine for cancer treatment, detection of genetic aberrations is the basis of developing effective treatment options. [30][31][32] Through the analysis of genetic mutations in patients with cancer, we can tailor the treatment plan for each patient with cancer to maximize the curative effect, minimize the damage, and optimize the resources. [33][34][35][36] Next-Generation Sequencing and Precise Targeting Therapy for Tumors Next-generation sequencing, also known as large-scale parallel sequencing, can simultaneously sequence millions or even billions of DNA molecules, achieving the goal of large-scale, high-throughput sequencing.…”

Section: Precision Medicine and Tumor Gene Detectionmentioning

confidence: 99%

See 1 more Smart Citation

Power and Promise of Next-Generation Sequencing in Liquid Biopsies and Cancer Control

Liu

et al. 2020

Cancer Control

View full text Add to dashboard Cite

Traditional methods of cancer treatment are usually based on the morphological and histological diagnosis of tumors, and they are not optimized according to the specific situation. Precision medicine adjusts the existing treatment regimen based on the patient’s genomic information to make it most suitable for patients. Detection of genetic mutations in tumors is the basis of precise cancer medicine. Through the analysis of genetic mutations in patients with cancer, we can tailor the treatment plan for each patient with cancer to maximize the curative effect, minimize damage to healthy tissues, and optimize resources. In recent years, next-generation sequencing technology has developed rapidly and has become the core technology of precise targeted therapy and immunotherapy for cancer. From early cancer screening to treatment guidance for patients with advanced cancer, liquid biopsy is increasingly used in cancer management. This is as a result of the development of better noninvasive, repeatable, sensitive, and accurate tools used in early screening, diagnosis, evaluation, and monitoring of patients. Cell-free DNA, which is a new noninvasive molecular pathological detection method, often carries tumor-specific gene changes. It plays an important role in optimizing treatment and evaluating the efficacy of different treatment options in clinical trials, and it has broad clinical applications.

show abstract

Section: Precision Medicine and Tumor Gene Detectionmentioning

confidence: 99%

Section: Precision Medicine and Tumor Gene Detectionmentioning

confidence: 99%

Power and Promise of Next-Generation Sequencing in Liquid Biopsies and Cancer Control

Liu

et al. 2020

Cancer Control

View full text Add to dashboard Cite

show abstract

“…In aggressive breast cancer cell lines, it was shown that polyarginine-PNA conjugated anti-miR-221 was specific for miR-221, and demonstrated efficient cellular uptake without the aid of transfection reagents [57]. Segal et al found that hydrophobically modified miRs (hmiR) added directly to culture medium or subcutaneously can enhance the biodistribution of the miRNAs in NSCLC [60].…”

Section: Systemic Deliverymentioning

confidence: 99%

microRNAs as Novel Therapeutics in Cancer

Romano

Acunzo

Nana‐Sinkam

2021

Cancers

View full text Add to dashboard Cite

In the last 20 years, the functional roles for miRNAs in gene regulation have been well established. MiRNAs act as regulators in virtually all biological pathways and thus have been implicated in numerous diseases, including cancer. They are particularly relevant in regulating the basic hallmarks of cancer, including apoptosis, proliferation, migration, and invasion. Despite the substantial progress made in identifying the molecular mechanisms driving the deregulation of miRNAs in cancer, the clinical translation of these important molecules to therapy remains in its infancy. The paucity of vehicles available for the safe and efficient delivery of miRNAs and ongoing concerns for toxicity remain major obstacles to clinical application. Novel formulations and the development of new vectors have significantly improved the stability of oligonucleotides, increasing the effectiveness of therapy. Furthermore, the use of specific moieties for delivery in target tissues or cells has increased the specificity of treatment. The use of new technologies has allowed small but important steps toward more specific therapeutic delivery in tumor tissues and cells. Although a long road remains, the path ahead holds great potential. Currently, a few miRNA drugs are under investigation in human clinical trials with promising results ahead.

show abstract

“…The rapid clearance of naked RNAs leads to a short life and instability. Chemically engineered miRNA modifications would be necessary to protect miRNAs from degradation and promote long-lasting potency (Segal et al, 2020). On the other hand, potential off-target effects of miRNAs (due to the imperfect complementarity with the 3' UTR of target genes) might cause undesirable silencing of other genes, potential toxicity, and reduced therapeutic efficacy.…”

Section: Perspectives and Challenges Of Developing Therapeutic Micrornasmentioning

confidence: 99%

Cell-Free Biological Approach for Corneal Stromal Wound Healing

2021

View full text Add to dashboard Cite

Corneal opacification is the fourth most common cause of blindness globally behind cataracts, glaucoma, and age-related macular degeneration. The standard treatment of serious corneal scarring is corneal transplantation. Though it is effective for restoring vision, the treatment outcome is not optimal, due to limitations such as long-term graft survival, lifelong use of immunosuppressants, and a loss of corneal strength. Regulation of corneal stromal wound healing, along with inhibition or downregulation of corneal scarring is a promising approach to prevent corneal opacification. Pharmacological approaches have been suggested, however these are fraught with side effects. Tissue healing is an intricate process that involves cell death, proliferation, differentiation, and remodeling of the extracellular matrix. Current research on stromal wound healing is focused on corneal characteristics such as the immune response, angiogenesis, and cell signaling. Indeed, promising new technologies with the potential to modulate wound healing are under development. In this review, we provide an overview of cell-free strategies and some approaches under development that have the potential to control stromal fibrosis and scarring, especially in the context of early intervention.

show abstract

Hydrophobically Modified let-7b miRNA Enhances Biodistribution to NSCLC and Downregulates HMGA2 In Vivo

Cited by 44 publications

References 66 publications

Power and Promise of Next-Generation Sequencing in Liquid Biopsies and Cancer Control

Power and Promise of Next-Generation Sequencing in Liquid Biopsies and Cancer Control

microRNAs as Novel Therapeutics in Cancer

Cell-Free Biological Approach for Corneal Stromal Wound Healing

Contact Info

Product

Resources

About